Corcept Therapeutics (CORT) Income from Continuing Operations (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Income from Continuing Operations data on file, last reported at 31715000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 254.57% year-over-year to 31715000.0; the trailing twelve-month figure through Mar 2026 stood at 47401000.0 (down 64.63% YoY), and the FY2025 full-year result was 99652000.0, down 29.43% from the prior year.
• Income from Continuing Operations eased to 31715000.0 in Q1 2026, from 24299000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 47243000.0 in Q3 2024 to a low of 31715000.0 in Q1 2026.
• A 5-year average of 24515000.0 and a median of 27530000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations jumped 89.07% in 2023 and sank 254.57% in 2026, its largest moves.
• Tracing CORT's Income from Continuing Operations over 5 years: stood at 16603000.0 in 2022, then surged by 89.07% to 31392000.0 in 2023, then fell by 2.06% to 30746000.0 in 2024, then slipped by 20.97% to 24299000.0 in 2025, then sank by 230.52% to 31715000.0 in 2026.
• Business Quant data shows CORT's Income from Continuing Operations at 31715000.0 in Q1 2026, 24299000.0 in Q4 2025, and 19668000.0 in Q3 2025.